Trastuzumab Deruxtecan (T-DXd) Alone or in Sequence With THP, Versus Standard Treatment (ddAC-THP), in HER2-positive Early Breast Cancer
Public ClinicalTrials.gov record NCT05113251. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 3 Open-label Trial of Neoadjuvant Trastuzumab Deruxtecan (T-DXd) Monotherapy or T-DXd Followed by THP Compared to ddAC-THP in Participants With High-risk HER2-positive Early-stage Breast Cancer (DESTINY-Breast11)
Study identification
- NCT ID
- NCT05113251
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Phase 3
- Lead sponsor
- AstraZeneca
- Industry
- Enrollment
- 927 participants
Conditions and interventions
Interventions
- Trastuzumab Deruxtecan Drug
- Paclitaxel Drug
- Trastuzumab Drug
- Pertuzumab Drug
- Doxorubicin Drug
- cyclophosphamide Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Oct 24, 2021
- Primary completion
- Mar 11, 2025
- Completion
- Apr 29, 2027
- Last update posted
- Jun 8, 2026
2021 – 2027
United States locations
- U.S. sites
- 22
- U.S. states
- 16
- U.S. cities
- 22
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Research Site | Springdale | Arkansas | 72762 | — |
| Research Site | Beverly Hills | California | 90211 | — |
| Research Site | Glendale | California | 91204 | — |
| Research Site | Los Alamitos | California | 90720 | — |
| Research Site | Orange | California | 92868 | — |
| Research Site | New Haven | Connecticut | 06510 | — |
| Research Site | Fort Wayne | Indiana | 46804 | — |
| Research Site | Lexington | Kentucky | 40503 | — |
| Research Site | Louisville | Kentucky | 40202 | — |
| Research Site | Shreveport | Louisiana | 71101 | — |
| Research Site | Minneapolis | Minnesota | 55407 | — |
| Research Site | Las Vegas | Nevada | 89102 | — |
| Research Site | East Brunswick | New Jersey | 08816 | — |
| Research Site | Summit | New Jersey | 07901 | — |
| Research Site | Commack | New York | 11725 | — |
| Research Site | Durham | North Carolina | 27710 | — |
| Research Site | Greenville | South Carolina | 29607 | — |
| Research Site | Germantown | Tennessee | 38138 | — |
| Research Site | Nashville | Tennessee | 37203 | — |
| Research Site | Fort Worth | Texas | 76104 | — |
| Research Site | Ogden | Utah | 84405 | — |
| Research Site | Tacoma | Washington | 98405 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 123 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05113251, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jun 8, 2026 · Synced Jul 24, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT05113251 live on ClinicalTrials.gov.